Discovery of medically significant lantibiotics

Current Drug Discovery Technologies

Volumn 6, Issue 1, 2009, Pages 1-18

  Piper, Clare ^a   Cotter, Paul D ^a   Ross, R Paul ^b,c   Hill, Colin ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c TEAGASC   (Ireland)

Author keywords

Antimicrobial peptide; Bacteriocin; Lantibiotic; MRSA; VRE

Indexed keywords

ACTAGARDIN; BACTERIOCIN; DALBAVANCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DURAMYCIN; EPIDERMIN; LACTICIN 3147; LANTHIOPEPTIN; LANTIBIOTIC; LINEZOLID; MERSACIDIN; MUTACIN; NISIN; ORITAVANCIN; PEP5 PEPTIDE; PLANOSPORICIN; PLANTARICIN C; POLYPEPTIDE ANTIBIOTIC AGENT; QUINUPRISTIN; RAMOPLANIN; TELEVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BIOENGINEERING; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; ENTEROCOCCUS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIOCINS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 62149120629     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309787581075     Document Type: Review

References (253)

1. Chambers H.F.: The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7(2), 178, (2001).
2. Jevons M.P.: "Celbenin"-resistant staphylococci. Bri. Med. J. Vol. 1, pp. 124-125, (1961).
3. Robinson D.A., Enright M.C.: Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents. Chemother. 47(12), 3926, (2003).
4. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E.: Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368(9538), 874, (2006).
5. Fey P.D., Said-Salim B., Rupp M.E., Hinrichs S.H., Boxrud D.J., Davis C.C., Kreiswirth B.N., Schlievert P.M.: Comparative molecular analysis of community-or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents. Chemother. 47(1), 196, (2003).
6. Okuma K., Iwakawa K., Turnidge J.D., Grubb W.B., Bell J.M., O'Brien F.G., Coombs G.W., Pearman J.W., et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J. Clin. Microbiol. 40(11), 4289, (2002).
7. Baba T., Takeuchi F., Kuroda M., Yuzawa H., Aoki K., Oguchi A., Nagai Y., Iwama N., et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359(9320), 1819, (2002).
8. Voyich J.M., Braughton K.R., Sturdevant D.E., Whitney A.R., Said-Salim B., Porcella S.F., Long R.D., Dorward D.W., et al.: Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol. 175(6), 3907, (2005).
9. Carleton H.A., Diep B.A., Charlebois E.D., Sensabaugh G.F., Perdreau-Remington F.: Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J. Infect. Dis. 190(10), 1730, (2004).
10. Harbarth S., Sax H., Gastmeier P.: The preventable proportion of nosocomial infections: an overview of published reports. J. Hosp. Infect. 54(4), 258, (2003).
11. Souvenir D., Anderson D.E., Jr., Palpant S., Mroch H., Askin S., Anderson J., Claridge J., Eiland J., et al.: Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J. Clin. Microbiol. 36(7), 1923, (1998).
12. Sader H.S., Jones R.N., Andrade-Baiocchi S., Biedenbach D.J.: Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn. Microbiol. Infect. Dis. 44(3), 273, (2002).
13. Vuong C., Otto M.: Staphylococcus epidermidis infections. Microbes. Infect. 4(4), 481, (2002).
14. Fontana M.B., de Bastos Mdo C., Brandelli A.: Bacteriocins Pep5 and epidermin inhibit Staphylococcus epidermidis adhesion to catheters. Curr. Microbiol. 52(5), 350, (2006).
15. Cetinkaya Y., Falk P., Mayhall C.G.: Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 13(4), 686, (2000).
16. Parenti F.: Structure and mechanism of action of teicoplanin. J. Hosp. Infect. 7 (Suppl A), 79, (1986).
17. Johnson A.P., Uttley A.H., Woodford N., George R.C.: Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3(3), 280, (1990).
18. Breukink E., de Kruijff B.: Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5(4), 321, (2006).
19. Brotz H., Bierbaum G., Leopold K., Reynolds P.E., Sahl H.G.: The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 42(1), 154, (1998).
20. Barna J.C., Williams D.H.: The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38, 339, (1984).
21. Cui L., Iwamoto A., Lian J.Q., Neoh H.M., Maruyama T., Horikawa Y., Hiramatsu K.: Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50(2), 428, (2006).
22. Hasper H.E., Kramer N.E., Smith J.L., Hillman J.D., Zachariah C., Kuipers O.P., de Kruijff B., Breukink E.: An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313(5793), 1636, (2006).
23. Hughes D.: Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Genet. 4(6), 432, (2003).
24. Arthur M., Molinas C., Depardieu F., Courvalin P.: Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 175(1), 117, (1993).
25. Fines M., Perichon B., Reynolds P., Sahm D.F., Courvalin P.: VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob. Agents Chemother. 43(9), 2161, (1999).
26. Perichon B., Reynolds P., Courvalin P.: VanD-type glycopeptide- resistant Enterococcus faecium BM4339. Antimicrob. Agents Chemother. 41(9), 2016, (1997).
27. Leclercq R., Dutka-Malen S., Duval J., Courvalin P.: Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob. Agents Chemother. 36(9), 2005, (1992).
28. Navarro F., Courvalin P.: Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob. Agents Chemother. 38(8), 1788, (1994).
29. Quintiliani R., Jr., Evers S., Courvalin P.: The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167(5), 1220, (1993).
30. Quintiliani R., Jr., Courvalin P.: Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol. Lett. 119(3), 359, (1994).
31. Courvalin P.: Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42 Suppl 1, S25, (2006).
32. Depardieu F., Reynolds P.E., Courvalin P.: VanD-type vancomycin-resistant Enterococcus faecium 10/96A. Antimicrob. Agents Chemother. 47(1), 7, (2003).
33. McKessar S.J., Berry A.M., Bell J.M., Turnidge J.D., Paton J.C.: Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob. Agents Chemother. 44(11), 3224, (2000).
34. Noble W.C., Virani Z., Cree R.G.: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 72(2), 195, (1992).
35. Howden B.P., Johnson P.D., Ward P.B., Stinear T.P., Davies J.K.: Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50(9), 3039, (2006).
36. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348(14), 1342, (2003).
37. CDC: Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly Rep. 51(26), 565, (2002).
38. CDC: Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. 51(40), 902, (2002).
39. CDC: Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal. Wkly. Rep. 53(15), 322, (2004).
40. Witte W.: Glycopeptide resistant Staphylococcus. J. Vet. Med. B. Infect. Dis Vet Public Health 51(8-9), 370, (2004).
41. Bataineh A.: Resistance of Staphylococcus aureus to vancomycin in Zarqa, Jordan. Pak. J. Med. Sci. 22, 144, (2006).
42. Palazzo I.C., Araujo M.L., Darini A.L.: First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. J. Clin. Microbiol. 43(1), 179, (2005).
43. Tiwari H.K., Sen M.R.: Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC. Infect. Dis. Vol. 6, pp. 156, (2006).
44. Liu C., Chambers H.F.: Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47(10), 3040, (2003).
45. Cui L., Ma X., Sato K., Okuma K., Tenover F.C., Mamizuka E.M., Gemmell C.G., Kim M.N., et al.: Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41(1), 5, (2003).
46. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., Tenover F.C., Zervos M.J., et al.: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340(7), 493, (1999).
47. Hiramatsu K.: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1(3), 147, (2001).
48. Hanaki H., Kuwahara-Arai K., Boyle-Vavra S., Daum R.S., Labischinski H., Hiramatsu K.: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42(2), 199, (1998).
49. Howden B.P., Ward P.B., Johnson P.D., Charles P.G., Grayson M.L.: Low-level vancomycin resistance in Staphylococcus aureus - an Australian perspective. Eur. J. Clin. Microbiol. Infect. Dis. 24(2), 100, (2005).
50. Appelbaum P.C.: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12 Suppl 1, 16, (2006).
51. Micek S.T.: Alternatives to Vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45 (Suppl 3), S184, (2007).
52. Enoch D.A., Bygott J.M., Daly M.L., Karas J.A.: Daptomycin. J. Infect. 55(3), 205-13, (2007).
53. Fuchs P.C., Barry A.L., Brown S.D.: In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49(3), 467, (2002).
54. Sum P.E., Petersen P.: Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9(10), 1459, (1999).
55. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T.: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43(4), 738, (1999).
56. Petersen P.J., Bradford P.A.: Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49(9), 3910, (2005).
57. Dizbay M., Kilic S., Hizel K., Arman D.: Tigecycline: its potential for treatment of brucellosis. Scand. J. Infect. Dis. 39(5), 432, (2007).
58. Livermore D.M.: Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51 Suppl 2, ii9, (2003).
59. Tunger A., Aydemir S., Uluer S., Cilli F.: In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci. Indian. J. Med. Res. 120(6), 546, (2004).
60. Eliopoulos G.M.: Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36(4), 473, (2003).
61. Luh K.T., Hsueh P.R., Teng L.J., Pan H.J., Chen Y.C., Lu J.J., Wu J.J., Ho S.W.: Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. 44(12), 3374, (2000).
62. Ballow C.H., Jones R.N., Biedenbach D.J.: A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43(1), 75, (2002).
63. Auckland C., Teare L., Cooke F., Kaufmann M.E., Warner M., Jones G., Bamford K., Ayles H., et al.: Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50(5), 743, (2002).
64. Herrero I.A., Issa N.C., Patel R.: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346(11), 867, (2002).
65. Johnson A.P., Tysall L., Stockdale M.V., Woodford N., Kaufmann M.E., Warner M., Livermore D.M., Asboth F., et al.: Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 21(10), 751, (2002).
66. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., Quinn J.P.: Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35(10), 1269, (2002).
67. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., Ferraro M.J.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207, (2001).
68. Rybak M.J., Hershberger E., Moldovan T., Grucz R.G.: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and - resistant strains. Antimicrob. Agents Chemother. 44(4), 1062, (2000).
69. Blondeau J.M., Sanche S.E.: Quinupristin/dalfopristin. Expert Opin. Pharmacother. 3(9), 1341, (2002).
70. Baddour M.M., Abuelkheir M.M., Fatani A.J.: Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann Clin. Microbiol. Antimicrob. 5(30, (2006).
71. Eiff C., Peters, G.: Comparitive in vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J. Antimicrob. Chemother. 43, 569, (1999).
72. Harrison C.J.: Quinupristin/dalfopristin. Semin. Pediatr. Infect. Dis. 12(3), 200, (2001).
73. Lamb H.M., Figgitt D.P., Faulds D.: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 58(6), 1061, (1999).
74. McCafferty D.G., Cudic P., Frankel B.A., Barkallah S., Kruger R.G., Li W.: Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66(4), 261, (2002).
75. Cudic P., Kranz J.K., Behenna D.C., Kruger R.G., Tadesse H., Wand A.J., Veklich Y.I., Weisel J.W., et al.: Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. Proc. Natl. Acad. Sci. USA 99(11), 7384, (2002).
76. Malabarba A., Goldstein B.P.: Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55 Suppl 2, ii15, (2005).
77. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., Sandvik E., Hubbard J.M., et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 1127, (2005).
78. Mercier R.C., Hrebickova L.: Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti. Infect. Ther. 3(3), 325, (2005).
79. Judice J.K., Pace J.L.: Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. 13(23), 4165, (2003).
80. Kerns R., Dong, S.D., Fukuzawa, S., Carbeck, J., Kohler, J., Silver, L., Kahne, D. The role of hydrophobic substituents in the biological activity of glycopetide antibiotics. J. Amer. Chem. Soc. 122(12608, (2002).
81. King A., Phillips I., Kaniga K.: Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53(5), 797, (2004).
82. Decousser J.W., Bourgeois-Nicolaos N., Doucet-Populaire F.: Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Expert Rev. Anti. Infect. Ther. 5(4), 557, (2007).
83. Biedenbach D.J., Ross J.E., Fritsche T.R., Sader H.S., Jones R.N.: Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 45(3), 998, (2007).
84. Allen N.E., Hobbs J.N., Jr., Nicas T.I.: Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 40(10), 2356, (1996).
85. Allen N.E., LeTourneau D.L., Hobbs J.N., Jr.: The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J. Antibiot. (Tokyo) 50(8), 677, (1997).
86. Allen N.E., LeTourneau D.L., Hobbs J.N., Jr., Thompson R.C.: Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies. Antimicrob. Agents Chemother. 46(8), 2344, (2002).
87. Beauregard D.A., Williams D.H., Gwynn M.N., Knowles D.J.: Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39(3), 781, (1995).
88. Chen L., Walker D., Sun B., Hu Y., Walker S., Kahne D.: Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. Proc. Natl. Acad. Sci. USA 100(10), 5658, (2003).
89. Ge M., Chen Z., Onishi H.R., Kohler J., Silver L.L., Kerns R., Fukuzawa S., Thompson C., et al.: Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284(5413), 507, (1999).
90. Goldman R.C., Baizman E.R., Longley C.B., Branstrom A.A.: Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding. FEMS Microbiol. Lett. 183(2), 209, (2000).
91. Pag U., Sahl H.G.: Multiple activities in lantibiotics - models for the design of novel antibiotics? Curr. Pharm. Des. 8(9), 815, (2002).
92. Rogers L.A., Whittier E.O.: Limiting Factors in the Lactic Fermentation. J. Bacteriol. 16(4), 211, (1928).
93. Cotter P.D., Hill C., Ross R.P.: Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3(10), 777, (2005).
94. Chan W.C., Leyland M., Clark J., Dodd H.M., Lian L.Y., Gasson M.J., Bycroft B.W., Roberts G.C.: Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. FEBS Lett. 390(2), 129, (1996).
95. Sahl H.G., Bierbaum G.: Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Annu. Rev. Microbiol. 52, 41, (1998).
96. de Vos W.M., Kuipers, O.P., van der Meer, J.R., Siezen, R.J.: Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria. Mol. Microbiol. 17(3), 427, (1995).
97. Sahl H.G., Jack R.W., Bierbaum G.: Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur. J. Biochem. 230(3), 827, (1995).
98. Hechard Y., Sahl H.G.: Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 84(5-6), 545, (2002).
99. McAuliffe O., Ross R.P., Hill C.: Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol. Rev. 25(3), 285, (2001).
100. Kuipers O.P., Rollema H.S., Yap W.M., Boot H.J., Siezen R.J., de Vos W.M.: Engineering dehydrated amino acid residues in the antimicrobial peptide nisin. J. Biol. Chem. 267(34), 24340, (1992).
101. Kleinkauf H., von Dohren H.: Biosynthesis of peptide antibiotics. Annu. Rev. Microbiol. 41, 259, (1987).
102. Cotter P.D., Hill C., Ross R.P.: Bacterial lantibiotics: strategies to improve therapeutic potential. Curr. Prot. Pept. Sci. 6(1), 61, (2005).
103. Cotter P.D., Deegan L.H., Lawton E.M., Draper L.A., O'Connor P.M., Hill C., Ross R.P.: Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol. Microbiol. 62(3), 735, (2006).
104. Willey J.M., van der Donk W.A.: Lantibiotics: peptides of diverse structure and function. Annu. Rev. Microbiol. 61, 477-501, (2007).
105. Okeley N.M., Paul M., Stasser J.P., Blackburn N., van der Donk W.A.: SpaC and NisC, the cyclases involved in subtilin and nisin biosynthesis, are zinc proteins. Biochemistry 42(46), 13613, (2003).
106. Ryan M.P., Rea M.C., Hill C., Ross R.P.: An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broadspectrum bacteriocin, lacticin 3147. Appl. Environ. Microbiol. 62(2), 612, (1996).
107. Navaratna M.A., Sahl H.G., Tagg J.R.: Two-component anti-Staphylococcus aureus lantibiotic activity produced by Staphylococcus aureus C55. Appl. Environ. Microbiol. 64(12), 4803, (1998).
108. McClerren A.L., Cooper L.E., Quan C., Thomas P.M., Kelleher N.L., van der Donk W.A.: Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc. Natl. Acad. Sci. USA 103(46), 17243, (2006).
109. Lawton E.M., Cotter P.D., Hill C., Ross R.P.: Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol. Lett. 267(1), 64, (2007).
110. Yonezawa H., Kuramitsu H.K.: Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob. Agents Chemother. 49(2), 541, (2005).
111. Gilmore M.S., Segarra R.A., Booth M.C.: An HlyB-type function is required for expression of the Enterococcus faecalis hemolysin/bacteriocin. Infect. Immun. 58(12), 3914, (1990).
112. Holo H., Jeknic Z., Daeschel M., Stevanovic S., Nes I.F.: Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 147(Pt 3), 643, (2001).
113. Hyink O., Balakrishnan M., Tagg J.R.: Streptococcus rattus strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol. Lett. 252(2), 235, (2005).
114. McAuliffe O., Hill C., Ross R.P.: Each peptide of the two-component lantibiotic lacticin 3147 requires a separate modification enzyme for activity. Microbiology 146(Pt 9) 2147, (2000).
115. Kodani S., Hudson M.E., Durrant M.C., Buttner M.J., Nodwell J.R., Willey J.M.: The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. Proc. Natl. Acad. Sci. USA 101(31), 11448, (2004).
116. Kodani S., Lodato M.A., Durrant M.C., Picart F., Willey J.M.: SapT, a lanthionine-containing peptide involved in aerial hyphae formation in the streptomycetes. Mol. Microbiol. 58(5), 1368, (2005).
117. Willey J.M., Willems A., Kodani S., Nodwell J.R.: Morphogenetic surfactants and their role in the formation of aerial hyphae in Streptomyces coelicolor. Mol. Microbiol. 59(3), 731, (2006).
118. Ueda K., Oinuma K., Ikeda G., Hosono K., Ohnishi Y., Horinouchi S., Beppu T.: AmfS, an extracellular peptidic morphogen in Streptomyces griseus. J. Bacteriol. 184(5), 1488, (2002).
119. Widdick D.A., Dodd H.M., Barraille P., White J., Stein T.H., Chater K.F., Gasson M.J., Bibb M.J.: Cloning and engineering of the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005. Proc. Natl. Acad. Sci. USA 100(7), 4316, (2003).
120. Zimmermann N., Freund S., Fredenhagen A., Jung G.: Solution structures of the lantibiotics duramycin B and C. Eur. J. Biochem. 216(2), 419, (1993).
121. Hsu S.T., Breukink E., Tischenko E., Lutters M.A., de Kruijff B., Kaptein R., Bonvin A.M., van Nuland N.A.: The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11(10), 963, (2004).
122. Breukink E.: A lesson in efficient killing from two-component lantibiotics. Mol. Microbiol. 61(2), 271, (2006).
123. Breukink E., Wiedemann I., van Kraaij C., Kuipers O.P., Sahl H., de Kruijff B.: Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286(5448), 2361, (1999).
124. Brotz H., Josten M., Wiedemann I., Schneider U., Gotz F., Bierbaum G., Sahl H.G.: Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30(2), 317, (1998).
125. Wiedemann I., Breukink E., van Kraaij C., Kuipers O.P., Bierbaum G., de Kruijff B., Sahl H.G.: Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276(3), 1772, (2001).
126. Breukink E., de Kruijff B.: The lantibiotic nisin, a special case or not? Biochim. Biophys. Acta 1462(1-2), 223, (1999).
127. Hasper H.E., de Kruijff B., Breukink E.: Assembly and stability of nisin-lipid II pores. Biochemistry 43(36), 11567, (2004).
128. Wiedemann I., Benz R., Sahl H.G.: Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J. Bacteriol. 186(10), 3259, (2004).
129. Bierbaum G., Sahl H.G.: Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch. Microbiol. 141(3), 249, (1985).
130. Daniel R.A., Errington J.: Control of cell morphogenesis in bacteria: two distinct ways to make a rod-shaped cell. Cell 113(6), 767, (2003).
131. Wescombe P.A., Tagg J.R.: Purification and characterization of streptin, a type A1 lantibiotic produced by Streptococcus pyogenes. Appl. Environ. Microbiol. 69(5), 2737, (2003).
132. Allgaier H., Jung G., Werner R.G., Schneider U., Zahner H.: Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic. Eur. J. Biochem. 160(1), 9, (1986).
133. Jack R.W., Jung G.: Lantibiotics and microcins: polypeptides with unusual chemical diversity. Curr. Opin. Chem. Biol. 4(3), 310, (2000).
134. Kellner R., Jung G., Horner T., Zahner H., Schnell N., Entian K.D., Gotz F.: Gallidermin: a new lanthionine-containing polypeptide antibiotic. Eur. J. Biochem. 177(1), 53, (1988).
135. Bonelli R.R., Schneider T., Sahl H.G., Wiedemann I.: Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob. Agents Chemother. 50(4), 1449, (2006).
136. Kupke T., Kempter C., Jung G., Gotz F.: Oxidative decarboxylation of peptides catalyzed by flavoprotein EpiD. Determination of substrate specificity using peptide libraries and neutral loss mass spectrometry. J. Biol. Chem. 270(19), 11282, (1995).
137. Sahl H.G., Brandis H.: Production, purification and chemical properties of an antistaphylococcal agent produced by Staphylococcus epidermidis. J. Gen. Microbiol. 127(2), 377, (1981).
138. Sahl H.G.: Staphylococcin 1580 is identical to the lantibiotic epidermin: implications for the nature of bacteriocins from gram-positive bacteria. Appl. Environ. Microbiol. 60(2), 752, (1994).
139. Sahl, H. G.: Pore formation in bacterial membranes by cationic lantibiotics. Nisin and Novel Lantibiotics. Eds.; H.-G. Sahl. 347, (1991).
140. Sahl H.G.: Influence of the staphylococcinlike peptide Pep 5 on membrane potential of bacterial cells and cytoplasmic membrane vesicles. J. Bacteriol. 162(2), 833, (1985).
141. Sahl H.G., Brandis H.: Mode of action of the staphylococcin-like peptide Pep 5 and culture conditions effecting its activity. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 252(2), 166, (1982).
142. Gonzalez B., Arca P., Mayo B., Suarez J.E.: Detection, purification, and partial characterization of plantaricin C, a bacteriocin produced by a Lactobacillus plantarum strain of dairy origin. Appl. Environ. Microbiol. 60(6), 2158, (1994).
143. Wiedemann I., Bottiger T., Bonelli R.R., Wiese A., Hagge S.O., Gutsmann T., Seydel U., Deegan L., et al.: The mode of action of the lantibiotic lacticin 3147 - a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 61(2), 285, (2006).
144. Brotz H., Bierbaum G., Markus A., Molitor E., Sahl H.G.: Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob. Agents Chemother. 39(3), 714, (1995).
145. Altena K., Guder A., Cramer C., Bierbaum G.: Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Appl. Environ. Microbiol. 66(6), 2565, (2000).
146. Chatterjee S., Chatterjee S., Lad S.J., Phansalkar M.S., Rupp R.H., Ganguli B.N., Fehlhaber H.W., Kogler H.: Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J. Antibiot. (Tokyo) 45(6), 832, (1992).
147. Brotz H., Bierbaum G., Reynolds P.E., Sahl H.G.: The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 246(1), 193, (1997).
148. Hsu S.T., Breukink E., Bierbaum G., Sahl H.G., de Kruijff B., Kaptein R., van Nuland N.A., Bonvin A.M.: NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278(15), 13110, (2003).
149. Fredenhagen, A., Marki, F., Fendrich, G., Marki, W., Gruner, J., van Oostrum, J., Raschdorf, F., Peter, H.H.: Duramycin B and C, two new lanthionine-containing antibiotics as inhibitors of phospholipase A2, and structural revision of duramycin and cinnamycin. Nisin and Novel Lantibiotics. Eds.; Jung, G. Sahl, H.-G. 131, (1991).
150. Jung G.: Lantibiotics- ribosomally synthesized biologically active polypetides containing sulfide bridges and α,β- didehydroamino acids. Angew. Chem. Int. Ed. Engl. 30, 1051, (1991).
151. Kessler, H., Seip, S., Wein, T., Steuernagel, S., Will, M.: The structure of cinnamycin (Ro 09-0198) in solution. Nisin and Novel Lantibiotics. Eds.; Jung, G., Sahl, H.-G. 76, (1991).
152. Chen L., Tai P.C.: Effects of antibiotics and other inhibitors on ATP-dependent protein translocation into membrane vesicles. J. Bacteriol. 169(6), 2373, (1987).
153. Navarro J., Chabot J., Sherrill K., Aneja R., Zahler S.A., Racker E.: Interaction of duramycin with artificial and natural membranes. Biochemistry 24(17), 4645, (1985).
154. Xie X.S., Stone D.K., Racker E.: Determinants of clathrin-coated vesicle acidification. J. Biol. Chem. 258(24), 14834, (1983).
155. Stone D.K., Xie X.S., Racker E.: Inhibition of clathrin-coated vesicle acidification by duramycin. J. Biol. Chem. 259(5), 2701, (1984).
156. Nakamura S., Racker E.: Inhibitory effect of duramycin on partial reactions catalyzed by (Na+,K+)-adenosinetriphosphatase from dog kidney. Biochemistry 23(2), 385, (1984).
157. Hosoda K., Ohya M., Kohno T., Maeda T., Endo S., Wakamatsu K.: Structure determination of an immunopotentiator peptide, cinnamycin, complexed with lysophosphatidylethanolamine by 1H-NMR1. J. Biochem. (Tokyo) 119(2), 226, (1996).
158. Marki F., Hanni E., Fredenhagen A., van Oostrum J.: Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem. Pharmacol. 42(10), 2027, (1991).
159. Choung S.Y., Kobayashi T., Inoue J., Takemoto K., Ishitsuka H., Inoue K.: Hemolytic activity of a cyclic peptide Ro09-0198 isolated from Streptoverticillium. Biochim. Biophys. Acta 940(2), 171, (1988).
160. Marki F., Franson R.: Endogenous suppression of neutral-active and calcium-dependent phospholipase A2 in human polymorphonuclear leukocytes. Biochim. Biophys. Acta 879(2), 149, (1986).
161. Aranha C., Gupta S., Reddy K.V.: Contraceptive efficacy of antimicrobial peptide Nisin: in vitro and in vivo studies. Contraception 69(4), 333, (2004).
162. Reddy K.V., Aranha C., Gupta S.M., Yedery R.D.: Evaluation of antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies. Reproduction 128(1), 117, (2004).
163. Zendo T., Fukao M., Ueda K., Higuchi T., Nakayama J., Sonomoto K.: Identification of the lantibiotic nisin Q, a new natural nisin variant produced by Lactococcus lactis 61-14 isolated from a river in Japan. Biosci. Biotechnol. Biochem. 67(7), 1616, (2003).
164. Wirawan R.E., Klesse N.A., Jack R.W., Tagg J.R.: Molecular and genetic characterization of a novel nisin variant produced by Streptococcus uberis. Appl. Environ. Microbiol. 72(2), 1148, (2006).
165. Mulders J.W., Boerrigter I.J., Rollema H.S., Siezen R.J., de Vos W.M.: Identification and characterization of the lantibiotic nisin Z, a natural nisin variant. Eur. J. Biochem. 201(3), 581, (1991).
166. Morency H., Mota-Meira M., LaPointe G., Lacroix C., Lavoie M.C.: Comparison of the activity spectra against pathogens of bacterial strains producing a mutacin or a lantibiotic. Can. J. Microbiol. 47(4), 322, (2001).
167. Severina E., Severin A., Tomasz A.: Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J. Antimicrob. Chemother. 41(3), 341, (1998).
168. Goldstein B.P., Wei, J., Greenberg, K., Novick, R.: Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J. Antimicrob. Chemother. 42(2), 277, (1998).
169. Pittet D., Tarara D., Wenzel R.P.: Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271(20), 1598, (1994).
170. Bower C.K., Bothwell M.K., McGuire J.: Lantibiotics as surface active agents for biomedical applications. Colloids Surf B: Biointerfaces 22(4), 259, (2001).
171. Bower C.K., Daeschel M.A., McGuire J.: Protein antimicrobial barriers to bacterial adhesion. J. Dairy Sci. 81(10), 2771, (1998).
172. Spencer R.C.: Clinical impact and associated costs of Clostridium difficile-associated disease. J. Antimicrob. Chemother. 41 Suppl C, 5, (1998).
173. Aslam S., Hamill R.J., Musher D.M.: Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5(9), 549, (2005).
174. Bricker E., Garg R., Nelson R., Loza A., Novak T., Hansen J.: Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. (1) CD004610, (2005).
175. Ohl M.E., Stevermer J.J., Meadows S., Tribuna J., Chek K.: Clinical inquiries. What are effective therapies for Clostridium difficile-associated diarrhea? J. Fam. Pract. 54(2), 176, (2005).
176. Barbut F., Decre D., Burghoffer B., Lesage D., Delisle F., Lalande V., Delmee M., Avesani V., et al.: Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43(11), 2607, (1999).
177. Bartoloni A., Mantella A., Goldstein B.P., Dei R., Benedetti M., Sbaragli S., Paradisi F.: In-vitro activity of nisin against clinical isolates of Clostridium difficile. J. Chemother. 16(2), 119, (2004).
178. Kerr K.G., Copley R.M., Wilcoy M.H.: Activity of nisin against Clostridium difficile. Lancet 349(9057), 1026, (1997).
179. Kuwano K., Tanaka N., Shimizu T., Nagatoshi K., Nou S., Sonomoto K.: Dual antibacterial mechanisms of nisin Z against Gram-positive and Gram-negative bacteria. Int J. Antimicrob. Agents 26(5), 396, (2005).
180. Hancock R.E.: Peptide antibiotics. Lancet 349(9049), 418, (1997).
181. Falla T.J., Karunaratne D.N., Hancock R.E.: Mode of action of the antimicrobial peptide indolicidin. J. Biol. Chem. 271(32), 19298, (1996).
182. Falla T.J., Hancock R.E.: Improved activity of a synthetic indolicidin analog. Antimicrob. Agents Chemother. 41(4), 771, (1997).
183. Peterson W.L., Fendrick A.M., Cave D.R., Peura D.A., Garabedian-Ruffalo S.M., Laine L.: Helicobacter pylori-related disease: guidelines for testing and treatment. Arch. Intern. Med. 160(9), 1285, (2000).
184. Dore M.P., Piana A., Carta M., Atzei A., Are B.M., Mura I., Massarelli G., Maida A., et al.: Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 12(7), 635, (1998).
185. Midolo P.D., Korman M.G., Turnidge J.D., Lambert J.R.: Helicobacter pylori resistance to tetracycline. Lancet 347(9009), 1194, (1996).
186. Simsek H., Kadayifci A., Tatar G.: Low eradication rates of Helicobacter pylori with omeprazole plus amoxycillin combination in a Turkish population. Am. J. Gastroenterol. 91(5), 1062, (1996).
187. Kim T.S., Hur J.W., Yu M.A., Cheigh C.I., Kim K.N., Hwang J.K., Pyun Y.R.: Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J. Food Prot. 66(1), 3, (2003).
188. Mota-Meira M., LaPointe G., Lacroix C., Lavoie M.C.: MICs of mutacin BNy266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob. Agents Chemother. 44(1), 24, (2000).
189. Giacometti A., Cirioni O., Barchiesi F., Scalise G.: In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diagn. Microbiol. Infect. Dis. 38(2), 115, (2000).
190. Giacometti A., Cirioni O., Greganti G., Quarta M., Scalise G.: In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Antimicrob. Agents Chemother. 42(12), 3320, (1998).
191. Livermore D.M., Chen H.Y.: Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J. Antimicrob. Chemother. 40(3), 335, (1997).
192. Brumfitt W., Salton M.R., Hamilton-Miller J.M.: Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 50(5), 731, (2002).
193. Netz D.J., Sahl H.G., Marcelino R., dos Santos Nascimento J., de Oliveira S.S., Soares M.B., do Carmo de Freire Bastos M.: Molecular characterisation of aureocin A70, a multi-peptide bacteriocin isolated from Staphylococcus aureus. J. Mol. Biol. 311(5), 939, (2001).
194. Nascimento J.S., Ceotto H., Nascimento S.B., Giambiagi-Demarval M., Santos K.R., Bastos M.C.: Bacteriocins as alternative agents for control of multiresistant staphylococcal strains. Lett. Appl. Microbiol. 42(3), 215, (2006).
195. Nascimento J S., Giambiagi-deMarval M., de Oliveira S.S., Ceotto H., dos Santos K.R., Bastos Mdo C.: Genomic fingerprinting of bacteriocin-producer strains of Staphylococcus aureus. Res. Microbiol. 156(8), 837, (2005).
196. Santos K.R.N., Fonseca, L.S., Gontijo Filho, P.P.: Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus: isolated from Brazilian university hospitals. Infect. Control. Hosp. Epidemiol. 17(813, (1996).
197. Raad I., Darouiche R., Dupuis J., Abi-Said D., Gabrielli A., Hachem R., Wall M., Harris R., et al.: Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann. Intern. Med. 127(4), 267, (1997).
198. Raad I.L.: Vascular catheters impregnated with antimicrobial agents: present knowledge and future direction. Infect Control Hosp Epidemiol. 18(4), 227, (1997).
199. Hamada S., Ooshima T.: Production and properties of bacteriocins (mutacins) from Streptococcus mutans. Arch. Oral. Biol. 20(10), 641, (1975).
200. Morency H., Trahan, L., Lavoie, C. M.: Preliminary grouping of mutacins Can. J. Microbiol. 41(826, (1995).
201. Mota-Meira M., Lacroix C., LaPointe G., Lavoie M.C.: Purification and structure of mutacin B-Ny266: a new lantibiotic produced by Streptococcus mutans. FEBS Lett. 410(2-3), 275, (1997).
202. Novak J., Caufield P.W., Miller E.J.: Isolation and biochemical characterization of a novel lantibiotic mutacin from Streptococcus mutans. J. Bacteriol. 176(14), 4316, (1994).
203. Parrot M., Charest M., Lavoie M.C.: Production of mutacin-like substances by Streptococcus mutans. Can. J. Microbiol. 35(3), 366, (1989).
204. Mota-Meira M., Morency H., Lavoie M.C.: In vivo activity of mutacin B-Ny266. J. Antimicrob. Chemother. 56(5), 869, (2005).
205. Niu W.W., Neu H.C.: Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin. Antimicrob. Agents Chemother. 35(5), 998, (1991).
206. Chatterjee S., Chatterjee D.K., Jani R.H., Blumbach J., Ganguli B.N., Klesel N., Limbert M., Seibert G.: Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. (Tokyo) 45(6), 839, (1992).
207. Kruszewska D., Sahl H.G., Bierbaum G., Pag U., Hynes S.O., Ljungh A.: Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54(3), 648, (2004).
208. Cole A.M., Tahk S., Oren A., Yoshioka D., Kim Y.H., Park A., Ganz T.: Determinants of Staphylococcus aureus nasal carriage. Clin. Diagn. Lab. Immunol. 8(6), 1064, (2001).
209. Kluytmans J., van Belkum A., Verbrugh H.: Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10(3), 505, (1997).
210. Peacock S.J., de Silva I., Lowy F.D.: What determines nasal carriage of Staphylococcus aureus? Trends Microbiol. 9(12), 605, (2001).
211. Boyce J.M.: Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect. Control Hosp. Epidemiol. 17(12), 775, (1996).
212. Fernandez C., Gaspar C., Torrellas A., Vindel A., Saez-Nieto J.A., Cruzet F., Aguilar L.: A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J. Antimicrob. Chemother. 35(3), 399, (1995).
213. Redhead R.J., Lamb Y.J., Rowsell R.B.: The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage. Br. J. Clin. Pract. 45(4), 252, (1991).
214. Krishnan P.U., Miles K., Shetty N.: Detection of methicillin and mupirocin resistance in Staphylococcus aureus isolates using conventional and molecular methods: a descriptive study from a burns unit with high prevalence of MRSA. J. Clin. Pathol. 55(10), 745, (2002).
215. Vivoni A.M., Santos K.R., de-Oliveira M.P., Giambiagi-deMarval M., Ferreira A.L., Riley L.W., Moreira B.M.: Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect. Control Hosp. Epidemiol. 26(7), 662, (2005).
216. Rupp M.E., Archer G.L.: Coagulase-negative staphylococci: pathogens associated with medical progress. Clin. Infect. Dis. 19(2), 231, (1994).
217. Upton A., Lang S., Heffernan H.: Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J. Antimicrob. Chemother. 51(3), 613, (2003).
218. Castiglione F., Cavaletti L., Losi D., Lazzarini A., Carrano L., Feroggio M., Ciciliato I., Corti E., et al.: A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp. Biochemistry 46(20), 5884, (2007).
219. Corti A., Rurali C., Borghi A., Cassani G.: Solid-phase enzyme-receptor assay (SPERA): a competitive-binding assay for glycopeptide antibiotics of the vancomycin class. Clin. Chem. 31(10), 1606, (1985).
220. Parenti F., Pagani H., Beretta G.: Gardimycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J. Antibiot. (Tokyo) 29(5), 501, (1976).
221. Somma S., Merati W., Parenti F.: Gardimycin, a new antibiotic inhibiting peptidoglycan synthesis. Antimicrob. Agents Chemother. 11(3), 396, (1977).
222. Cannon J.P., Lee T.A., Bolanos J.T., Danziger L.H.: Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur. J. Clin. Microbiol. Infect. Dis. 24(1), 31, (2005).
223. Galvin M., Hill C., Ross R.P.: Lacticin 3147 displays activity in buffer against gram-positive bacterial pathogens which appear insensitive in standard plate assays. Lett. Appl. Microbiol. 28(5), 355, (1999).
224. Rea M.C., Clayton E., O'Connor P M., Shanahan F., Kiely B., Ross R.P., Hill C.: Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J. Med. Microbiol. 56(Pt 7), 940, (2007).
225. Le Blay G., Lacroix C., Zihler A., Fliss I.: In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. Lett. Appl. Microbiol. 45(3), 252, (2007).
226. Dajani A.S., Gray E.D., Wannamaker L.W.: Bactericidal substance from Staphylococcus aureus. Biological properties. J. Exp. Med. 131(5), 1004, (1970).
227. O'Connor E.B., Cotter P.D., O'Connor P., O'Sullivan O., Tagg J.R., Ross R.P., Hill C.: Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity. BMC Microbiol. 7(24, (2007).
228. Paik S.H., Chakicherla A., Hansen J.N.: Identification and characterization of the structural and transporter genes for, and the chemical and biological properties of, sublancin 168, a novel lantibiotic produced by Bacillus subtilis 168. J. Biol. Chem. 273(36), 23134, (1998).
229. Stein T., Borchert S., Conrad B., Feesche J., Hofemeister B., Hofemeister J., Entian K.D.: Two different lantibiotic-like peptides originate from the ericin gene cluster of Bacillus subtilis A1/3. J. Bacteriol. 184(6), 1703, (2002).
230. Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N., Fuji F., Hirama C., et al.: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and genomic sequence comparison with Bacillus subtilis. Nucleic Acids Res. 28(21), 4317, (2000).
231. Rollema H.S., Kuipers O.P., Both P., de Vos W.M., Siezen R.J.: Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl. Environ. Microbiol. 61(8), 2873, (1995).
232. Ottenwalder B., Kupke T., Brecht S., Gnau V., Metzger J., Jung G., Gotz F.: Isolation and characterization of genetically engineered gallidermin and epidermin analogs. Appl. Environ. Microbiol. 61(11), 3894, (1995).
233. Yuan J., Zhang Z.Z., Chen X.Z., Yang W., Huan L.D.: Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. Appl. Microbiol. Biotechnol. 64(6), 806, (2004).
234. Rink R., Kuipers A., de Boef E., Leenhouts K.J., Driessen A.J., Moll G.N., Kuipers O.P.: Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochemistry 44(24), 8873, (2005).
235. Field D., Collins B., Cotter P.D., Hill C., Ross R.P.: A system for the random mutagenesis of the two-Peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities. J. Mol. Microbiol. Biotechnol. 13(4), 226, (2007).
236. Nagao J., Aso Y., Shioya K., Nakayama J., Sonomoto K.: Lantibiotic engineering: molecular characterization and exploitation of lantibiotic- synthesizing enzymes for Peptide engineering. J. Mol. Microbiol. Biotechnol. 13(4), 235, (2007).
237. Paul M., van der Donk, W.A.: Chemical and enzymatic synthesis of lanthionines. Mini Rev. Org. Chem. 2, 23, (2005).
238. Bierbaum G., Szekat C., Josten M., Heidrich C., Kempter C., Jung G., Sahl H.G.: Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Appl. Environ. Microbiol. 62(2), 385, (1996).
239. Svensson C.I., Rew Y., Malkmus S., Schiller P.W., Taulane J.P., Goodman M., Yaksh T.L.: Systemic and spinal analgesic activity of a delta-opioid-selective lanthionine enkephalin analog. J. Pharmacol. Exp. Ther. 304(2), 827, (2003).
240. van der Meer J.R., Polman J., Beerthuyzen M.M., Siezen R.J., Kuipers O.P., De Vos W.M.: Characterization of the Lactococcus lactis nisin A operon genes nisP, encoding a subtilisin-like serine protease involved in precursor processing, and nisR, encoding a regulatory protein involved in nisin biosynthesis. J. Bacteriol. 175(9), 2578, (1993).
241. Chatterjee C., Patton G.C., Cooper L., Paul M., van der Donk W.A.: Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. Chem. Biol. 13(10), 1109, (2006).
242. Kluskens L.D., Kuipers A., Rink R., de Boef E., Fekken S., Driessen A.J., Kuipers O.P., Moll G.N.: Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin. Biochemistry 44(38), 12827, (2005).
243. Kuipers A., de Boef E., Rink R., Fekken S., Kluskens L.D., Driessen A.J., Leenhouts K., Kuipers O.P., et al.: NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides. J. Biol. Chem. 279(21), 22176, (2004).
244. Szekat C., Jack R.W., Skutlarek D., Farber H., Bierbaum G.: Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl. Environ. Microbiol. 69(7), 3777, (2003).
245. Cheng F., Takala T.M., Saris P.E.: Nisin Biosynthesis in vitro. J. Mol. Microbiol. Biotechnol. 13(4), 248, (2007).
246. Li B., Yu J.P., Brunzelle J.S., Moll G.N., van der Donk W.A., Nair S.K.: Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science 311(5766), 1464, (2006).
247. Fukase K., Wakamiya, T., Shiba, T.: Synthetic study on peptide antibiotic nisin. II. The synthesis of Ring B. Bull. Chem. Soc. Jpn. 59, 2505, (1985).
248. Avenoza A., Busto J.H., Jimenez-Oses G., Peregrina J.M.: Stereoselective synthesis of orthogonally protected alpha- methylnorlanthionine. Org. Lett. 8(13), 2855, (2006).
249. Bregant S., Tabor A.B.: Orthogonally protected lanthionines: synthesis and use for the solid-phase synthesis of an analogue of nisin ring C. J. Org. Chem. 70(7), 2430, (2005).
250. Ghalit N., Reichwein J.F., Hilbers H.W., Breukink E., Rijkers D.T., Liskamp R.M.: Synthesis of Bicyclic Alkene-/Alkane-Bridged Nisin Mimics by Ring-Closing Metathesis and their Biochemical Evaluation as Lipid II Binders: toward the Design of Potential Novel Antibiotics. Chembiochem. 8(13), 1540, (2007).
251. Cobb S.L., Vederas J.C.: A concise stereoselective synthesis of orthogonally protected lanthionine and beta-methyllanthionine. Org. Biomol. Chem. 5(7), 1031, (2007).
252. Matteucci M., Bhalay G., Bradley M.: Cystine mimetics - solid phase lanthionine synthesis. Tetrahedron Letts. 45(7), 1399, (2004).
253. Narayan R.S., Vannieuwenhze M.S.: Versatile and stereoselective syntheses of orthogonally protected beta-methylcysteine and beta- methyllanthionine. Org. Lett. 7(13), 2655, (2005).